Jpmorgan Chase & CO Pro Qr Therapeutics N.V. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PRQR
# of Institutions
53Shares Held
17.3MCall Options Held
26.2KPut Options Held
8.6K-
Privium Fund Management B.V.5.63MShares$20.4 Million2.56% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$13.2 Million0.01% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.04MShares$7.42 Million0.12% of portfolio
-
M28 Capital Management LP Stamford, CT1.02MShares$3.7 Million1.95% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA906KShares$3.29 Million0.39% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $259M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...